Register an account to search through 14,000+ stocks! 

Ad

NUVB – Nuvation Bio Inc

Ad

Compliant

★★★★☆

Industry: Biotechnology & Medical Research | NYSE

Nuvation Bio Inc is Shariah compliant. The company’s financials pass four standards and fail in one.

Market cap: 931 MRev. Growth: %

AAOIFI ✗

Debt/MC0%
Non-Compliant Assets/MC67.95%

S&P ✓

Debt/36 mo MC0%
Cash/36 mo MC9.78%
AR/36 mo MC%

DJIM ✓

Debt/24 mo MC0%
Cash/24 mo MC9.78%
AR/24 mo MC%

FTSE ✓

Debt/Assets0%
Cash/Assets17.06%
Cash&AR/Assets17.06%

MSCI ✓

Debt/Assets0%
Cash/Assets17.06%
Cash&AR/Assets17.06%

Recommendation Rating

1.57

1

2

3

4

5

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 14.67

Low: 12

High: 17

Total Analysts: 7


Nuvation Bio Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing differentiated and novel therapeutic candidates focused on treating patients with cancer. The Company is advancing six wholly owned compounds that have resulted from drug discovery and development programs, which include NUV-422 a cyclin-dependent kinase (CDK) inhibitor, NUV-868 a bromodomain and extra terminal (BET) inhibitor, NUV-569 a Wee1 inhibitor, an A2A adenosine receptor inhibitor program, and a drug-drug conjugate (DDC) platform. Its lead product candidate, NUV-422, is a selective small molecule inhibitor of CDK 2, 4 and 6. Its second product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. It is developing, including NUV-569, NUV-569 is a differentiated oral small molecule selective inhibitor of Wee1 kinase, an important regulator of deoxyribonucleic acid (DNA) damage repair. Its subsidiaries include Nuvation Holdings, LLC and RePharmation Ltd.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan.

To understand how the screening is done, please read the Shariah Screening Methodology page.

Ad

Responses